First drug to slow Alzheimer’s disease could soon be on the market

Aducanumab appears to ‘reduce clinical decline’ of patients in early stages

Chiara Giordano
Wednesday 23 October 2019 00:37
Comments
Drug company Biogen says it will seek approval in the US for a medicine to slow early Alzheimer's disease.
Drug company Biogen says it will seek approval in the US for a medicine to slow early Alzheimer's disease.

A potentially “ground-breaking” drug which appears to slow Alzheimer’s disease could soon change the lives of thousands of dementia sufferers.

The treatment offers new hope to patients in the early stages of the most common form of dementia, which affects about 850,000 people living in the UK.

Biogen says its drug, aducanumab, would be the first treatment to “reduce the clinical decline” of patients in the early stages of Alzheimer’s disease if approved.

The company is now seeking regulatory approval for the drug in the US after new analysis of trial data revealed some patients experienced benefits in memory, orientation, language and everyday living skills such as shopping and doing laundry.

Reacting to the company's announcement, Hilary Evans, chief executive of Alzheimer's Research UK, said: "People affected by Alzheimer's have waited a long time for a life-changing new treatment and this exciting announcement offers new hope that one could be in sight."

Dementia causes an ongoing decline in brain function, which can affect memory, thinking speed, speech, mood and movement.

The decision to seek regulatory approval of aducanumab comes after clinical studies ended in March this year.

Biogen said the findings of an initial analysis were "incorrect" with an examination of a larger dataset showing aducanumab reduced clinical decline in patients in the early stages of Alzheimer's.

The company said the positive results of the new analysis were driven by patients having a greater exposure to a high dose of aducanumab, a drug designed to help the body clear harmful plaques from the brain.

Ms Evans said: "As more data emerges, we hope it will spark global discussions about the next steps for delivering much-needed treatments into people's hands."

Biogen said it would submit a licence application for aducanumab in the US in early 2020.

Support free-thinking journalism and attend Independent events

It said it was continuing to speak to regulatory authorities in other markets, including Europe.

Michel Vounatsos, chief executive at Biogen, said: "With such a devastating disease that affects tens of millions worldwide, today's announcement is truly heartening in the fight against Alzheimer's.

"This is the result of groundbreaking research and is a testament to Biogen's steadfast determination to follow the science and do the right thing for patients."

Additional reporting by Press Association.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in